Abstract: Aspects of the present disclosure provide, inter alia, a novel nutritional formula for infants and toddlers. Also provided are methods for promoting development of infants and toddlers, such as development of the brain, eye and/or immune system, including in preterm infants.

Abstract: Aspects of the present disclosure provide, inter alia, a novel nutritional formula for infants and toddlers. Also provided are methods for promoting development of infants and toddlers, such as development of the brain, eye and/or immune system, including in preterm infants.

Abstract: The general inventive concepts are directed to compositions and methods for the prevention and treatment of dehydration. Provided herein are nutritional compositions including oral rehydration compositions. Certain embodiments of the nutritional compositions have an acidic pH, and comprise a digestible carbohydrate, sodium, citrate, and an oligosaccharide selected from a fucosylated oligosaccharide and an N-acetylated oligosaccharide.

Abstract: The general inventive concepts are directed to compositions and methods for the prevention and treatment of dehydration. Provided herein are nutritional compositions including oral rehydration compositions. Certain embodiments of the nutritional compositions have an acidic pH, and comprise a digestible carbohydrate, sodium, citrate, and an oligosaccharide selected from a fucosylated oligosaccharide and an N-acetylated oligosaccharide.

Abstract: The general inventive concepts are directed to compositions and methods for the prevention and treatment of dehydration. Provided herein are nutritional compositions including oral rehydration compositions. Certain embodiments of the nutritional compositions have an acidic pH, and comprise a digestible carbohydrate, sodium, citrate, and an oligosaccharide selected from a fucosylated oligosaccharide and an N-acetylated oligosaccharide.

Abstract: The general inventive concepts are directed to compositions and methods for the prevention and treatment of dehydration. Provided herein are nutritional compositions including oral rehydration compositions. Certain embodiments of the nutritional compositions have an acidic pH, and comprise a digestible carbohydrate, sodium, citrate, and an oligosaccharide selected from a fucosylated oligosaccharide and an N-acetylated oligosaccharide.

Abstract: Disclosed are infant formulas comprising at least about 6.5 g/L, on an as-fed basis, of an enriched whey protein concentrate, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. The formulas also typically include at least about 5 mg/L of gangliosides, at least about 150 mg/L of phospholipids, and at least about 70 mg/L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, all of which are provided in whole or in part from the enriched whey protein concentrate. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

Abstract: Disclosed are infant formulas comprising, on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. From about 50% to 100% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid is provided by an enriched whey protein concentrate, with the concentrate representing at least about 6.5 g/L of the formula on an as-fed basis. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

Abstract: Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, and (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

Abstract: Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis, at least about 5 mg/L of gangliosides, at least about 150 mg/L of phospholipids, at least about 70 mg/L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

Abstract: The subject invention relates to monovalent oligosaccharides and their use, for example, in the treatment and prevention of mammalian disease caused by HIV-1 virus infections. In particular, the oligosaccharides globotriose and lactose may be used alone or in combination to competitively inhibit the formation of the viral fusion complex that occurs upon infection.

Abstract: A wavefront aberration of an eye is determined, e.g., in real time. The eye is illuminated, and the light reflected from the retina is converted into spots with a device such as a Hartmann-Shack detector. The displacement of each spot from where it would be in the absence of aberration allows calculation of the aberration. Each spot is located by an iterative technique in which a corresponding centroid is located in a box drawn on the image data, a smaller box is defined around the centroid, the centroid is located in the smaller box, and so on. The wavefront aberration is calculated from the centroid locations by using a matrix in which unusable data can be eliminated simply by eliminating rows of the matrix. Aberrations for different pupil sizes are handled in data taken for a single pupil size by renormalization.

Abstract: A wavefront aberration of an eye is determined, e.g., in real time. The eye is illuminated, and the light reflected from the retina is converted into spots with a device such as a Hartmann-Shack detector. The displacement of each spot from where it would be in the absence of aberration allows calculation of the aberration. Each spot is located by an iterative technique in which a corresponding centroid is located in a box drawn on the image data, a smaller box is defined around the centroid, the centroid is located in the smaller box, and so on. The wavefront aberration is calculated from the centroid locations by using a matrix in which unusable data can be eliminated simply by eliminating rows of the matrix. Aberrations for different pupil sizes are handled in data taken for a single pupil size by renormalization.

Abstract: A wavefront aberration of an eye is determined, e.g., in real time. The eye is illuminated, and the light reflected from the retina is converted into spots with a device such as a Hartmann-Shack detector. The displacement of each spot from where it would be in the absence of aberration allows calculation of the aberration. Each spot is located by an iterative technique in which a corresponding centroid is located in a box drawn on the image data, a smaller box is defined around the centroid, the centroid is located in the smaller box, and so on. The wavefront aberration is calculated from the centroid locations by using a matrix in which unusable data can be eliminated simply by eliminating rows of the matrix. Aberrations for different pupil sizes are handled in data taken for a single pupil size by renormalization.